502424224 07/18/2013

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date		
NOVARTIS PHARMA AG	01/19/2009		

RECEIVING PARTY DATA

Name:	NOVARTIS AG
Street Address:	LICHTSTRASSE 35
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4056

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11523978

CORRESPONDENCE DATA

Fax Number: 9737818064

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: pip_inbox.phchbs@novartis.com

Correspondent Name: NOVARTIS

Address Line 1: MICHAEL J. MAZZA

Address Line 2: ONE HEALTH PLAZA, BLDG. 101

Address Line 4: EAST HANOVER, NEW JERSEY 07936-1080

ATTORNEY DOCKET NUMBER:	PAT053326-US-CNT02
NAME OF SUBMITTER:	Michael J. MAZZA
Signature:	/Michael J. Mazza/
Date:	07/18/2013

Total Attachments: 4

source=11523978_Assgn_NAG#page1.tif source=11523978_Assgn_NAG#page2.tif source=11523978_Assgn_NAG#page3.tif source=11523978_Assgn_NAG#page4.tif

> PATENT REEL: 030824 FRAME: 0365

TCH \$40.00 11523978

ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

Novartis Pharma AG, a company organized under the laws of the Switzerland, of Lichtstrasse 35, CH-4002, Basel, Switzerland

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all of our right, title and interest for all countries of the world (Novartis AG hereinafter referred to collectively as the "ASSIGNEES") in and to those patents and patent applications set forth on Schedules A and B hereto (collectively, the "ASSIGNED PATENTS"), as well as any extensions, divisions, reexaminations, reissues and continuations thereof and any applications or patents that claim priority from such patents and applications, including any foreign counterparts thereto, and all rights, claims and privileges pertaining to any of the foregoing.

	Executed this	day of Leave	<u>: </u>	<u>) J</u> .		
,	NOVARTIS PHAR	MA AG				
W.1	Intel (allow	l S			
ĺ	Time Villet ME Duly anthorize	MEC Arthor	- CANON	164		
7.	July authorize	d signatori	~~			
	ACKNOWLEDGEME	NT				
	State of					
	County of) s.s.:)				
	On this	iay of me known and known	, 20	_, personally appe	eared before me	executed
	the foregoing Assignm purpose set forth.	nent and acknowledge	ed that (s)he ex	recuted the same	of his (her) own free	e will for the
	(Seal)					

Notary Public

Attestation

I, the undersigned notary public of Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the above signatures are the genuine signatures of **Ms. June Violet Mentel**, citizen of Grenchen/SO, Switzerland, residing in Arlesheim/BL, Switzerland, and of **Mr. Arthur Canonica**, citizen of Corticiasca/TI, Switzerland, residing in Wisen/SO, Switzerland, both acting for **Novartis Pharma AG**, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signatures was established by means of comparison.

Basel, Switzerland, this 21st (twenty-first) day of January 2009 (two thousand and nine)

THIAS STARTED IN

M. Stacker Notes

Dr. M. Stachelin

Notar

Leg. Prot. Nr. 295 /2009

PATENT REEL: 030824 FRAME: 0367

SCHEDULE A TO ASSIGNMENT

[See Attachment]

PATENT REEL: 030824 FRAME: 0368

MATTER NO	COUNTRY	SERIAL NO	PATENT NO	PUBL NO	TILE .	RELATED	ŜTATUŜ	FILE	PÜBL	ISSUE	EXPIRATION
0242.20	US	11/523,978	7	US-2007- 0123477-A1	COMPOSITIONS COMPRISING AMPHOTERICIN B, METHODS, AND SYSTEMS	0242.00	PUBLISHED	9 /20/2006	5 /31/2007		6 /21/2025
0231.PRO	US	60/583,878			AEROSOLIZABLE FORMULATION COMPRISING NICOTINE		EXPIRED	6 /28/2004			6 /28/2005
0231.00	US	11/169,153		US-2006- 0018840-A1	AEROSOLIZABLE FORMULATION COMPRISING NICOTINE	0231.PRO	PUBLISHED	6 /28/2005	1 /26/2006		6 /28/2025
0244.PRO MM	US	60/598,282			STABLE ORAL FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR		EXPIRED	8 /2 /2004			8 /2 /2005
0251.PRO MM	US			,	STABLE AMORPHOUS, SOLID, FORMULATIONS OF LOSARTAN POTASSIUM		ABANDONED				12/6 /2004
0213.PRO2	ŲS	60/629,165			PHARMACEUTICAL FORMULATION WITH MULTIPLE ANTIBIOTICS		EXPIRED	11/18/200 4			11/18/2005
0261.PRO	US	60/633,991			STABLE NON- CRYSTALLINE FORMULATION COMPRISING TIAGABINE		EXPIRED	12/7 . /2004			12/7 /2005
0259.PRO	US	60/633,953			NON-CRYSTALLINE FORMULATION COMPRISING TIAGABINE		EXPIRED	12/7 /2004			12/7 /2005
0262.PRO MM	ÚS	60/640,316			NON-CRYSTALLINE FORMULATION COMPRISING FINASTERIDE		EXPIRED	12/30/200 4			12/30/2005
0263.PRO MM	US	60/640,315			NON-CRYSTALLINE FORMULATION COMPRISING CLOPIDOGREL		EXPIRED	12/30/200 4			12/30/2005
0258.PRO MM	US	60/633,990			NON-CRYSTALLINE FORMULATION COMPRISING DONEPEZIL		EXPIRED	12/7 /2004			12/7 /2005
0235.PRO MM	US	60/636,667			STABLE, NON- CRYSTALLINE FORMULATION COMPRISING OLANZAPINE		EXPIRED	12/16/200 4			12/16/2005